These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9435854)

  • 21. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
    Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
    J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells.
    Dmitriev I; Kashentseva E; Rogers BE; Krasnykh V; Curiel DT
    J Virol; 2000 Aug; 74(15):6875-84. PubMed ID: 10888627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
    J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding specificities and affinities of egf domains for ErbB receptors.
    Jones JT; Akita RW; Sliwkowski MX
    FEBS Lett; 1999 Mar; 447(2-3):227-31. PubMed ID: 10214951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.
    Vasiljevic S; Beale EV; Bonomelli C; Easthope IS; Pritchard LK; Seabright GE; Caputo AT; Scanlan CN; Dalziel M; Crispin M
    Mol Immunol; 2015 Dec; 68(2 Pt A):234-43. PubMed ID: 26391350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER4 receptor activation and phosphorylation of Shc proteins by recombinant heregulin-Fc fusion proteins.
    Culouscou JM; Carlton GW; Aruffo A
    J Biol Chem; 1995 May; 270(21):12857-63. PubMed ID: 7759543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
    Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
    Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
    Vallera DA; Zhang B; Gleason MK; Oh S; Weiner LM; Kaufman DS; McCullar V; Miller JS; Verneris MR
    Cancer Biother Radiopharm; 2013 May; 28(4):274-82. PubMed ID: 23611188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis.
    Jones JT; Ballinger MD; Pisacane PI; Lofgren JA; Fitzpatrick VD; Fairbrother WJ; Wells JA; Sliwkowski MX
    J Biol Chem; 1998 May; 273(19):11667-74. PubMed ID: 9565587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
    Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
    MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor.
    Wallace PK; Romet-Lemonne JL; Chokri M; Kasper LH; Fanger MW; Fadul CE
    Cancer Immunol Immunother; 2000 Nov; 49(9):493-503. PubMed ID: 11092616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with CD64-directed immunotherapy. An overview.
    Curnow RT
    Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
    Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
    J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.
    Klewinghaus D; Pekar L; Arras P; Krah S; Valldorf B; Kolmar H; Zielonka S
    Front Immunol; 2021; 12():801368. PubMed ID: 35087526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.